Why Gilead’s and Moderna’s Stocks Rallied Today

Gilead Sciences

Gilead (GILD) stock soared after market hours adding $11 to the $1.90 the stock had gained during trading hours. Investors’ enthusiasm was raised when very promising results came out of a clinical trial for Gilead’s drug remdesivir given to COVID-19 infected people.  

According to the news the University of Chicago’s Phase 3 trial results demonstrated that most COVID-19 infected patients treated with Gilead’s drug remdesivir experienced fast recoveries from fever and respiratory symptoms and were discharged in less than one week, reported by Health-care publication STAT News.

Leave a Reply